top of page

Insights and News Curated for Life Science Experts by Life Science Experts....

Go back to...
JMG Logo transparent.png
Executive Spotlights

Eli Lilly to Acquire Calytrix Bio for Up to $1.5B to Expand Neuroscience Drug Pipeline

1 day ago
1 min read

Indianapolis, IN, November 16, 2026 (Reuters) -- Eli Lilly and Company has agreed to acquire Calytrix Bio, a privately held biotechnology company developing treatments for neurological and neurodegenerative diseases, in a transaction valued at up to $1.5 billion. The deal includes an upfront payment and additional milestone-based payments tied to the achievement of specified development and commercial objectives. The acquisition is expected to strengthen Lilly's neuroscience portfolio and expand its pipeline of potential treatments for neurological disorders. The transaction reflects Lilly's continued investment in external innovation and its strategy to expand its presence in neuroscience alongside its established diabetes, obesity, and oncology businesses.



Read full article here.

 
 
 

Recent Posts

See All

Comments


Life Science Headlines
bottom of page